TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Cytomegalovirus Infection
Interventions
DRUG

Valganciclovir

900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks

Trial Locations (8)

Unknown

Hospital Clínico y Provincial de Barcelona, Barcelona

"Hospital Universitario Germans Trias i Pujol", Barcelona

Hospital Universitario de la Princesa, Madrid

Hospital Universitario Ramón y Cajal, Madrid, Madrid

Hospital Universitario Morales Meseguer, Murcia, Murcia

Hospital general de Jerez de la Frontera, Jerez de la Frontera

Hospital Universitario La Paz, Madrid

Hospital Clínico Universitario de Salamanca, Salamanca

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT00386412 - TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant | Biotech Hunter | Biotech Hunter